# Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

> **NCT00854737** · PHASE2 · COMPLETED · sponsor: **Mclean Hospital** · enrollment: 90 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DIETARY_SUPPLEMENT:** cytidine
- **DIETARY_SUPPLEMENT:** omega-3 fatty acids
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00854737
- **Lead sponsor:** Mclean Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-08
- **Final completion:** 2010-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854737, "Cytidine and Omega-3 Fatty Acids in Bipolar Disorder". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00854737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*